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Abstract
In this issue of Cancer Cell, Hydbring and colleagues define a novel class of microRNAs 
(miRNAs), deemed “cell-cycle-targeting miRNAs,” that target several cyclins/CDKs, reduce 
tumor cell growth, and induce apoptosis. These miRNAs effectively suppressed chemoresistant 
patient-derived xenograft growth in vivo, and efficacy could be prospectively predicted with an 
expression-based algorithm.
One of the hallmarks of cancer is unbridled cell proliferation, often manifesting through 
alterations of the cell-cycle machinery, including cyclin-dependent kinases (CDKs) and their 
cognate catalytic partners, the cyclins (Hanahan and Weinberg, 2011). Cyclin/CDK 
complexes regulate cell-cycle phase transitions through selective phosphorylation of 
substrates that control all aspects of cell division, including commitment to completion of a 
mitotic cell cycle, achieved through phosphorylation and inactivation of the retinoblastoma 
(RB) tumor suppressor protein. These functions are counterbalanced by canonical 
endogenous CDK inhibitors and tumor suppressors. Loss of these cell-cycle-attenuating 
tumor suppressors, or, by contrast, deregulation of cyclins, CDKs, or CDK targets, can 
afford a mechanism for tumor cells to bypass the appropriate cell-cycle regulation and occur 
at high frequency in human malignancies (Otto and Sicinski, 2017). As such, developing 
effective therapeutic means to thwart cell-cycle dysregulation may lead to significant benefit 
for cancer patients.
The study by Hydbring et al. brings understanding to the role of miRNAs in controlling cell-
cycle regulatory proteins and supports the concept that miRNA function could be harnessed 
as a means to counteract unchecked cell-cycle progression (summarized in Figure 1) 
(Hydbring et al., 2017). miRNAs are short, regulatory RNA species that reduce the 
expression of gene products by inducing mRNA degradation or inhibition of translation 
(Lagos-Quintana et al., 2001). Similar to the cell-cycle machinery, miRNAs show frequent 
*Correspondence: karen.knudsen@jefferson.edu. 
HHS Public Access
Author manuscript
Cancer Cell. Author manuscript; available in PMC 2018 April 10.
Published in final edited form as:
Cancer Cell. 2017 April 10; 31(4): 471–473. doi:10.1016/j.ccell.2017.03.012.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
alteration in human malignancy (Lu et al., 2005). Understanding of miRNA function is a 
fertile ground of current investigation, and a number of potential applications in both 
diagnostics and therapeutics have been realized (Adams et al., 2017; Hydbring and 
Badalian-Very, 2013). Hydbring et al. screened for miRNAs that target nine cyclins and 
CDKs of importance for cell division in cancer cells. The results of this screen revealed 30 
miRNAs with the capacity to target five or more cyclins/CDKs and 14 miRNAs capable of 
targeting six or more cyclins/CDKs, thus demonstrating a novel class of miRNAs that 
regulate nearly all components of the cell-cycle machinery. The number of miRNAs that 
target multiple cyclins/CDKs is significantly higher than predicted by chance alone. 
Furthermore, prioritization studies identified anti-correlation of selected miRNAs with 
anticipated cyclin/CDKs in human tumors, and the miRNAs were found to be 
downregulated or deleted in several tumor types.
Building upon these initial findings, a second screen utilizing a 122-cancer-cell-line library 
comprised of 12 tumor types was employed to test the efficacy of these cell-cycle-targeting 
miRNAs. Four miRNAs identified in the initial screen demonstrated significant growth-
inhibitory effects in the cell lines examined, albeit to differing magnitudes. Strikingly, cells 
derived from gastric cancers and triple-negative breast cancers (TNBCs) demonstrated a 
more robust response, potentially due to greater reliance on the targeted cyclins/CDKs. In 
these tissue types, it was further noted that cell-cycle-targeting miRNAs harbored the 
capacity to induce apoptosis, suggesting that the miRNAs elicit not only the expected 
cytostatic effects but also cytotoxic responses. Investigation of the underlying basis for 
enhanced responsiveness in TNBC and gastric cancer may therefore lay the foundation for 
determining which tumors may be most responsive to miR-based therapies targeting cell-
cycle regulation.
Recent clinical successes targeting CDK activity have increased enthusiasm for refining the 
means to suppress cell-cycle control in a subset of tumor types, most particularly as related 
to CDK4/6 inhibitors (CDK4/6i). The CDK4/6i palbociclib is FDA approved for the 
treatment of estrogen receptor (ER)-positive, HER2-negative advanced breast cancer in 
combination with estrogen deprivation or ER-targeted therapies (letrozole or fulvestrant, 
respectively) (Finn et al., 2015; Turner et al., 2015), based in part on clinical trial data 
demonstrating that the combination resulted in improved progression-free survival (PFS) 
compared to hormone therapy alone. More recently, the CDK4/6i ribociclib was FDA 
approved for this same patient population in combination with letrozole, based on clinical 
data indicating that the combination lengthened PFS (Hortobagyi et al., 2016). In principle, 
the studies here have the potential to build on the success of CDK4/6i, as the miRNAs 
identified proved capable of simultaneously suppressing more than five to six CDKs or 
cyclins and therefore could provide a more potent mechanism to suppress the cancer cell 
cycle. Furthermore, whereas CDK4/6i are approved for ER-positive disease, the data from 
Hydbring et al. identified ER-negative tumor models (TNBC) as exceptional responders to 
miRNA-based cell-cycle suppression. Head-to-head comparison revealed that miR193a-3p 
is more effective than palbociclib in blocking TNBC cell growth, and miR193a-3p elicits 
anti-tumor effects even in the context of RB loss, which renders cells resistant to palbociclib. 
miR193a-3p was also more effective than lapatinib in HER2-positive cells and was 
comparable to the combination of lapatinib and palbociclib. While these findings require 
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validation and development of translational potential, the study by Hydbring et al. provides 
robust evidence that cell-cycle-targeting miRNAs hold promise as anti-cancer agents that 
may hold advantages over CDK4/6 targeting alone in breast cancer.
Harnessing the miRNAs for translational potential yielded promising results in patient-
derived xenograft (PDX) models of chemotherapy-resistant TNBC and colorectal cancer. In 
both systems, miRNA-containing nanoparticles were effective in eliciting anti-tumor 
responses, whereas normal tissues were spared any toxicity. In a doxorubicin- and taxane-
resistant TNBC PDX, nanoparticles containing miR193a-3p reduced proliferation and 
induced apoptosis, demonstrating that cell-cycle-targeting miRNA therapy may be effective 
in chemotherapy-resistant tumors. Furthermore, in a KRAS mutant FOLFOX- and 
FOLFIRI-resistant colorectal tumor PDX, miR214-5p blocked tumor growth while sparing 
normal tissues and was more effective in KRAS mutant than wild-type cells. These data 
indicate that tumor phenotype and/or genotype may influence the utility of cell-cycle-
targeting miRNAs. Given the demonstrated selectivity, it is intriguing to speculate that the 
heightened reliance of tumor cells on cyclins/CDKs can be effectively targeted in malignant 
tissues using the cell-cycle-targeting miRNA strategy.
Hydbring et al. also developed an expression-based algorithm to predict responses to cell-
cycle-targeting miRNAs. As proof of principle, the authors transcriptionally profiled an 
aggressive dermatofibrosarcoma protuberans that was resistant to both Gleevec and PI3K 
inhibition. Utilizing the developed algorithm, it was predicted that the tumor would be 
responsive to miR-193a-3p. Subsequent administration of nanoparticles containing 
miR193a-3p to mice harboring a PDX of the dermatofibrosarcoma protuberans resulted in 
significant reduction of tumor growth, demonstrating the utility of the algorithm. Based on 
these exciting findings, future studies examining combinatorial strategies with cell-cycle-
targeting miRNAs may lead to effective means of managing malignancy.
There are currently three clinical trials utilizing miRNA-based therapies listed on 
www.clinicaltrials.gov. Two (NCT01829971, NCT02862145) were recently terminated due 
to immune-related serious adverse events, suggesting that a proper nomination schema, as 
might be done with the expression-based algorithm described by the authors, may be needed 
to optimize miRNA-based therapies. The third therapeutic miRNA trial is a phase I trial 
utilizing a miR-16 mimic in progressive mesothelioma and non-small-cell lung cancer 
(NCT02369198), which is employing an epidermal growth factor receptor-targeting 
mechanism. A targeting strategy may be needed to circumvent the possible toxicity of 
miRNA-based cancer therapy, although the work by Hydbring et al. demonstrates that use of 
nanoparticles to deliver cell-cycle-targeting miRNAs does not elicit toxicity in 
immunocompromised mice. Importantly, while several studies that have examined the 
capacity of miRNA-based technology to be clinically useful report mixed results, the 
strategy defined by the authors provides hope for using cell-cycle-targeting miRNAs for 
cancer management in the near future.
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Figure 1. Summary of Hydbring et al
Through several screens, it was determined that a subset of miRNAs target cyclins and 
CDKs, which are positive drivers of the cell cycle. These “cell-cycle-targeting miRNAs” 
were found to be inversely correlated with cyclins/CDKs in The Cancer Genome Atlas 
(TCGA) data, as well as either reduced or deleted in several tumor types. Therapeutic 
efficacy of these cell-cycle-targeting miRNAs was enriched in TNBC and gastric cancer cell 
lines, which was validated in chemotherapy-resistant PDX models.
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